VECIMA/VECTOR/LIBERTY
17.5.2021 14:02:57 CEST | Business Wire | Press release
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint.
The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency.
“The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generation broadband networks in Europe,” said Seamus Gallagher, Liberty Global’s VP of Access Network Strategy. “Currently, we have over 19 million homes connected throughout Europe with speeds of 1Gbps. DAA brings many benefits, such as increased network bandwidth and less equipment in the headend and hub by enabling a multi-service - video/data/voice/mobile backhaul - unified, fiber core network. We are excited to continue our gigabit rollout with a solution that helps avoid vendor lock-in and supports multi-vendor interoperability.”
Liberty Global, with support from Vecima and Vector Technologies, plans to complete field trials in Autumn 2021 in their Western and Central Europe operating companies. The trials showcase R-PHY’s operational efficiency and the planned deployment cement Liberty Global as a worldwide leader in next-gen gigabit broadband.
‟We are excited to partner with both Liberty Global and Vector Technologies to leverage our Entra DAA solutions to transform consumer experiences in homes, businesses, and anywhere that people connect,” said Clay McCreery, Chief Operating Officer at Vecima. “Utilizing existing network infrastructures, Vecima is committed to building and delivering the industry’s most innovative cable access solutions that will deliver ground-breaking speed and capacity. Liberty is one of the leading operators in the world, and we’re proud to help enable their strategic vision.”
Liberty Global requirements included a solution that was fully interoperable with their deployed CCAP Core platforms. The Vecima ERM112 RPD module gives Liberty Global the freedom to source access network elements from multiple vendors, enhancing cost efficiency and accelerating time to market. Vector Technologies acted as the integrator for the project and performed all necessary tests at its DAA and DOCSIS laboratories.
"Vector Technologies and Vecima built a solution that supports a standards-based, multi-vendor environment. We believe that openness is the key to building the access network of the future, and we are committed to building scalable, secure, and simple solutions to manage network solutions that avoid vendor lock-in scenarios," said Maciej Muzalewski, CTO of Vector Technologies. “ We performed all the essential tests at our high-tech laboratories, which we built to support future DOCSIS and DAA implementations. We are delighted to continue our partnership with Liberty Global as an integrator, helping them forge ahead to gigabit speeds across their footprint."
Bridging the new 10G digital fiber CIN networks and the legacy RF coax plant, the combined Vector Technologies and Vecima solution supports architectures that push fiber deeper into the network, allowing operators to leverage existing network capacity and deliver increased bandwidth to subscribers.
About Liberty Global
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is one of the world’s leading converged video, broadband and communications companies, with operations in seven European countries under the consumer brands Virgin Media, Telenet, UPC, the combined Sunrise UPC, as well as VodafoneZiggo, which is owned through a 50/50 joint venture. Our substantial scale and commitment to innovation enable us to invest in the infrastructure and digital platforms that empower our customers to make the most of the digital revolution.
Liberty Global delivers market-leading products through next-generation networks that connect customers subscribing to 50 million broadband, video, fixed and mobile telephony services across our brands. We also have significant investments in ITV, All3Media, ITI Neovision, LionsGate, the Formula E racing series and several regional sports networks.
For more information, please visit www.libertyglobal.com
.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery, and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high‑capacity broadband network access, and streamline data analytics.
Further information about Vecima’s Entra solution is available at https://vecima.com/solutions/distributed-access/
. Or visit our website at www.vecima.com
.
About Vector Technologies
Vector Technologies acts as a European competence center for the world’s largest Multiple System Operators and support them in network transformation towards Distributed Access Architecture.
As an experienced partner, we:
- integrate, optimize and design solutions for Next Generation Access Networks
- define the best directions of technological development in the area of Distributed Access Architecture (DAA) or Passive Optical Networks (PON) and Software-Defined Networking (SDN)
- support Multiple System Operators in the efficient technology migrations
- help operators in increasing efficiency and availability of provided services
- have proven field experience in managing turnkey projects for Remote-PHY, DAA, DOCSIS 3.1 and DOCSIS 3.0
For more information, updates and useful links, please visit our website: https://vectortechnologies.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom